The study’s multi-cancer early detection data show Exai’s RNA- and AI-based platform can detect multiple cancer types at the earliest stages using a single, standard blood sample.
Read More
A new class of blood-based biomarkers could be developed into improved or orthogonal tests for predicting tumor responses to treatment.
Read More
An artificial intelligence tool has successfully identified those at the highest risk for pancreatic cancer up to 3 years before diagnosis.
Read More
Experts argue that “test by request” have led to higher PSA testing and clear medical harm, with minimal benefit and inequity.
Read More
Adela demonstrated the ability of its genome-wide methylome enrichment platform to detect a broad set of diverse cancers in early stages.
Read More